September 25, 2019
1 min watch
Save

VIDEO: Top takeaways from ESC Congress with Dipti Itchhaporia, MD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARIS — In this video exclusive, Dipti Itchhaporia, MD, FACC, with Hoag Heart and Vascular Institute in Newport Beach and University of California, Irvine, and vice president-elect of the American College of Cardiology, provides highlights from the 2019 European Society of Cardiology Congress.

Topping her list are DAPA-HF, which studied the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with HF, with and without diabetes; COMPLETE, which compared complete revascularization and culprit lesion-only PCI in patients with STEMI and multivessel CAD; and ISAR-REACT 5, which evaluated outcomes with prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. ticagrelor (Brilinta, AstraZeneca) in patients with acute coronary syndromes.

Itchhaporia, a Cardiology Today Editorial Board Member, provides insight on these important trials.

Watch the video for more.